Interestingly, blocking Ang-II inhibits Spp1 expression in non-infarcted myocardium of post-MI hearts [63] and olmesartan, which is an Ang II receptor blocker, significantly decreases plasma OPN levels in patients with hypertension [66]. The gene discussed is SPP1; the disease is myocardial infarction.